Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers

Infection Control and Hospital Epidemiology

Volumn 33, Issue 12, 2012, Pages 1226-1234

  Teresa del Campo, M ^a   Fouad, Hadia ^a   Marcela Solis Bravo M ^b   Angeles Sanchez Uriz M ^b   Mahíllo Fernández, Ignacio ^a   Esteban, Jaime ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID;

ADULT; ARTICLE; BCG VACCINATION; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; QUANTIFERON TB GOLD; SCREENING TEST; TUBERCULIN TEST;

ADOLESCENT; ADULT; AGE FACTORS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DECISION TREES; FEMALE; HEALTH CARE COSTS; HOSPITALS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; OCCUPATIONAL DISEASES; ODDS RATIO; SPAIN; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84869195698     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/668436     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005;54(RR-17):1-141.
2. Salpeter SR, Salpeter EE. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 2004;25:1056-1061.
3. Cellestis. Clinical Experience with QuantiFERONf -TB Gold (In-Tube). http://www.cellestis.com/IRM/Company/ShowPage.aspx?CPID=1254. Published November 2001. Accessed December 3, 2011.
4. Girardi E, Angeletti C, Puro V, et al. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. Euro Surveill 2009;29: 14-43.
5. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25.
6. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. http://www.nice.org.uk/nicemedia/live/13422/53642/53642.pdf. Published March 2011. Accessed January 9, 2012.
7. Gonzalez J, Garc ́ia JM, Anibarro L, et al. Documento de consenso sobre diagnostico, tratamiento y prevencion de la tuberculosis. Enferm Infecc Microbiol Clin 2010;28:297.e1-e20.
8. Moreno S, Blazquez R, Novoa A, et al. The effect of BCG vaccination on tuberculin reactivity and the booster effect among hospital employees. Arch Intern Med 2001;161:1760-1765.
9. Shams H, Weis SE, Klucar P, et al. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005;172:1161-1168.
10. Diel R, Nienhaus A, Lange C, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28:35-44.
11. Ravn P, Munk ME, Andersen AB, et al. Prospective evaluation of a whole blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CEP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 2005;12:491-496.
12. Goletti D, Vincenti D, Carrara S, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorben assay and' an enzyme-linked immunospot assay. Clin Diagn Lab Immunol 2005;12:1311-1316.
13. Ferrara G, Losi M, Damico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet' 2006;367:1328-1334.
14. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis 1993;17:968-975.
15. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-7 release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007;131:1424-1434.
16. Schwartzman K, Menzies D. Tuberculosis screening of immi-' grants to low-prevalence countries: a cost-effectiveness analysis. Am J Respir Crit Care Med 2000;161:780-789.
17. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24-30.
18. Lobue PA, Catanzaro A. Effectiveness of a nosocomial tuberculosis control program at an urban teaching hospital. Chest 1998;113:1184-1189.
19. Taylor Z. The cost-effectiveness of screening for latent tuberculosis infection. Int J Tuberc Lung Dis 2000;4(suppl 2):S127-S133.
20. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;(2):CD001363.
21. Linertova R, Alvarez-Leon EE, García-Perez L, et al. Costs of QuantiFERON-TB Gold versus tuberculin skin test in Spanish healthcare workers. J Hosp Infect 2010;75:52-55.
22. Miller TL, Mcnabb SJ, Hilsenrath P, et al. The societal cost of tuberculosis: Tarrant County, Texas, 2002. Ann Epidemiol 2010; 20:1-7.
23. Pai M, Gokhale K, Joshi R, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole blood interferon y release assay with tuberculin skin' testing. JAMA 2005;293:2746-2755.
24. Mirtskulava V, Kempker R, Shields K, et al. Prevalence and risk factors for latent tuberculosis infection among health care workers in Georgia. Int J Tuberc Lung Dis 2008;12:513-519.
25. Harada N, Nakajima Y, Higuchi K, et al. Screening for tuber-culosis infection using whole-blood interferon-7 and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006;27:442-448.
26. Ciaschetti A, Franchi A, Richeldi L, et al. Screening of latent tuberculosis infection in healthcare workers by Quantiferon TB-G and tuberculin skin test. G Ital Med Lav Ergon 2007;29:406-407.
27. Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in healthcare setting. Int J Tuberc Lung Dis 2007;11:593-605.
28. Eum SY, Lee YJ, Kwak HK, et al. Evaluation of the diagnostic utility of a whole-blood interferon-7 assay for determining the risk of exposure to Mycobacterium tuberculosis in Bacille Calmette-Guerin (BCG)-vaccinated individuals. Diagn Microbiol Infect Dis 2008;61:181-186.
29. Sherman HA, Karakis I, Heimer D, et al. Housekeeping health care workers have the highest risk for tuberculin skin test conversion. Int J Tuberc Lung Dis 2011;15:1050-1055.
30. Pooran A, Booth H, Miller RF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010; 10:7
31. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007;11:16-26.
32. Servicio de Epidemiologi{dotless} ́a, Servicio Madrileno de Salud de la Comunidad de Madrid. Registro Regional de Casos de Tuberculosis en la Comunidad de Madrid: Informe del Ano 2009. http://www.madrid.org/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-disposition&blobheadername2=cadena&blobheadervalue1=filename%3DInforme+Regional+TB+2009.pdf&blobheadervalue2=language%3Des%26site%3DPortalSalud&blobkey=id&blobtable=MungoBlobs&blobwhere=1272102879448&ssbinary=true. Accessed January 9, 2012.
33. De Perio MA, Tsevat J, Roselle GA, et al. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in healthcare workers. Arch Intern Med 2009;169:179-187.
34. Fox BD, Kramer MR, Mor Z, et al. The Quantiferon-TB-Gold assay for tuberculosis screening in healthcare workers: a cost-comparison analysis. Lung 2009;187:413-419.
35. Nienhaus A, Schablon A, Torres Costa J, et al. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011;11(247):1-28.
36. Haagsma JA, Tariq L, Heederik DJ, et al. Infectious disease risks associated with occupational exposure: a systematic review of the literature. Occup Environ Med 2012;69:140-146.